What are you trying to do?
Pick a goal. We’ll show you the peptides in this library that address it, plus an honest label of whether the evidence is from research, community use, or a topical-only context. Click into any peptide for the full evidence-tiered profile, or add it straight to your stack from here.
Goals not listed (fertility, libido, mood, cognitive endurance, etc.) — the peptides in our current library don’t have strong evidence or established community use for those. Ask the AI on a specific peptide page if you have a particular question; it will be honest about what we know and don’t.
Weight management & metabolic health
The strongest-evidence corner of this library. The GLP-1 / GIP class has Tier 1 RCT data for both type 2 diabetes and chronic weight management. Several adjacent compounds add modest mechanistic options.
Curated stack
- TirzepatideDual GLP-1 + GIP agonist. SURMOUNT-1 showed up to −22.5% body weight at 72 weeks on 15 mg, with better lean-mass preservation than semaglutide. Choose one GLP-class core based on access, tolerance, and goal magnitude.
- RetatrutideInvestigational GLP-1 + GIP + glucagon triple agonist. Phase 2 showed −24.2% at 48 weeks on 12 mg — the largest non-surgical effect size to date, with the glucagon arm adding energy expenditure and hepatic fat oxidation. Choose one GLP-class core; not yet FDA-approved.
- SemaglutideGLP-1 monoagonist. Most established evidence base (STEP-1: −14.9% at 68 weeks; SELECT: cardiovascular benefit). The most familiar to clinicians and a reasonable starting point in the GLP-class core.
- CagriSemaCagriSema (cagrilintide + semaglutide) combination — REDEFINE 1 showed 22.7% loss at 68 weeks, exceeding semaglutide monotherapy. Useful when a patient is plateauing on semaglutide alone without further dose-escalation tolerance.
- CagrilintideAmylin analog adjunct. Most clinically interesting paired with a GLP-1 (above) as CagriSema; standalone data is thinner.
- AOD-9604Lipolytic adjunct, especially for stubborn fat or plateaus in already-lean individuals. Modest standalone effect; complements the GLP-class backbone by adding a direct fat-oxidation signal.
- CJC-1295 / IpamorelinGH/IGF-1 elevation helps preserve lean mass during aggressive caloric deficit — a leading driver of metabolic adaptation and post-cessation regain.
- MOTS-cExercise-mimetic adjunct via AMPK and insulin sensitivity. Stacked alongside SS-31 to push back against the metabolic-rate decline that accompanies any significant caloric deficit.
Incretin agonism is the most evidence-supported pharmacologic approach to weight management, but GLP-1 monotherapy leaves three problems on the table: metabolic-rate decline, lean-mass loss, and the lipolytic side of fat oxidation. A combined stack addresses incretin appetite suppression plus mitochondrial activation plus lean-mass preservation plus lipolytic signaling, and is more likely to produce durable results than monotherapy alone.
More peptides in this goal
Dual GIP/GLP-1 agonist. SURMOUNT-1 (n=2,539) showed 15–22% mean body weight reduction at 72 weeks. FDA-approved as Zepbound for chronic weight management.
GLP-1 agonist. STEP-1 showed 14.9% mean body weight reduction at 68 weeks. SELECT trial added a 20% reduction in major adverse cardiac events in the obesity + CVD population. FDA-approved as Wegovy.
Triple agonist (GLP-1 / GIP / glucagon) in late-stage trials. Phase 2 reported ~24% mean body weight reduction at 48 weeks — the largest non-surgical effect size in the GLP-1 family to date. Not yet FDA-approved.
Long-acting amylin analog. Most clinically interesting paired with semaglutide as CagriSema (Phase 2 ~15–17% weight loss); standalone data is thinner. Tier 2.
Semaglutide + cagrilintide combination. REDEFINE 1 showed 22.7% loss at 68 weeks. Plateau-rescue option for patients already on semaglutide.
GHRH analog approved for HIV-associated visceral fat. Off-label use targets visceral adipose reduction in non-HIV populations on the basis of the same mechanism.
Mitochondrial-derived peptide with rodent data on insulin sensitivity, fat oxidation, and exercise capacity. No completed human RCTs; community use as a metabolic adjunct is mechanism-as-evidence reasoning. Tier 3.
Modified C-terminal fragment of human GH (residues 176–191). Marketed as a fat-loss peptide; the original 2007 Phase 2 trial in obesity was unimpressive and the program did not advance. Tier 3.
Small-molecule NNMT inhibitor (not a peptide; included as a stack-companion). Strong rodent data on adipose-specific metabolic improvement; no published human trials. Tier 3 for the metabolic claim.
GHRH + GHRP blend. Community use as a lean-mass-preservation adjunct during caloric deficit. The mechanistic basis (overnight GH/IGF-1 pulse) is plausible; outcome data specifically for deficit settings is limited. Tier 3.
Recovery & tissue repair
Animal data for tendon, ligament, gut, and muscle healing is consistent across many models. Published human RCTs are largely absent — read the evidence tier carefully on each.
Mitochondrial + cofactor stack · 3 phases · guided multi-peptide program with decision criteria
Cofactor restoration → tissue repair → GH-axis (post-weaning) · 3 phases · guided multi-peptide program with decision criteria
Off-season tissue + GH-axis → peak metabolic + endurance (WADA-banned throughout) · 2 phases · guided multi-peptide program with decision criteria
Synthetic 15-amino-acid peptide derived from a gastric protein. Animal data is large and consistent; community uses it for tendons, ligaments, gut, and post-injury recovery. Tier 3.
Thymosin Beta-4 fragment. Animal evidence for cell migration and angiogenesis. Frequently stacked with BPC-157 in community recovery protocols. Tier 3 — and WADA-banned for competitive athletes.
28-amino-acid immunomodulator. Tier 1–2 for chronic hepatitis B/C in approved markets and as immune adjuvant; community recovery use draws on the immune-restorative framing rather than direct tissue-repair evidence.
Lysine-Proline-Valine, a 3-amino-acid C-terminal fragment of α-MSH. Anti-inflammatory mechanism via melanocortin pathway. Some preclinical IBD/wound-healing data. Tier 3.
Long Arg3 IGF-1 — long-acting analog of insulin-like growth factor 1. Community use targets anabolic recovery and lean-mass gain. WADA-banned. Tier 3 outside its diagnostic / endocrine-disorder use.
Longevity & GH-axis
Peptides that amplify the body's natural pulsatile growth hormone release. Most have plausible mechanisms but limited human outcomes data — read the tiers carefully.
Curated stack
- CJC-1295 / IpamorelinThe community-default GH-axis restoration pairing. GHRH analog plus a selective GHRP delivers a clean overnight GH pulse without the cortisol/prolactin elevation of older GHRPs.
- SermorelinOlder, well-characterized GHRH analog. Modest, mechanistically clean GH stimulation; the cleaner side-effect profile makes it a reasonable starting point or alternative to CJC/Ipa for users who prefer a single-peptide GHRH approach.
- TesamorelinStrongest evidence base of any GHRH analog (FDA-approved for HIV-associated visceral fat). The Tier 1 data for an approved indication anchors this corner of the GH-axis stack.
- MK-677 (Ibutamoren)Oral non-peptide ghrelin receptor agonist. Reliably elevates GH and IGF-1 in human studies; long half-life means side effects (water retention, appetite, sometimes insulin resistance) accumulate. Useful when injection burden is the limiting factor.
These three GHRH-class peptides restore the natural pulsatile growth-hormone signal that declines with age, working upstream rather than substituting exogenous GH. The mechanism is well understood and the side-effect profile is generally clean; outcome data outside approved indications (Tesamorelin for HIV lipodystrophy) is largely extrapolation. Choose one core based on protocol shape — daily pulses (CJC/Ipa, sermorelin) versus weekly dosing (with-DAC variants) versus the strongest off-label evidence base (tesamorelin).
More peptides in this goal
Selective GHRP — minimal cortisol or prolactin elevation, which is its main differentiator vs older GHRPs. Common pairing with CJC-1295 for synergistic GH release. Tier 3 for off-label longevity use.
GHRH analog. No-DAC form mimics natural pulses (multi-daily); with-DAC form sustains elevation (weekly). Almost always paired with a GHRP like ipamorelin. Tier 3.
The blend itself, supplied premixed by most compounding pharmacies. Convenience and dose consistency vs separately sourced peptides.
Strongest evidence base of any GHRH analog (FDA-approved for HIV lipodystrophy). Off-label community use targets the same GH/IGF-1 axis effects.
Older GHRH analog. Was FDA-approved for pediatric GH deficiency (later withdrawn). Modest, mechanistically clean GH stimulation. Tier 2 in approved indications, Tier 3 for adult longevity use.
Oral non-peptide ghrelin receptor agonist (Ibutamoren). Reliably elevates GH and IGF-1 in human studies. Long half-life means side effects (water retention, increased appetite, sometimes insulin resistance) accumulate. Tier 2 for the GH/IGF-1 elevation, Tier 3 for outcome claims.
Older GHRP. Tier 1 as a diagnostic GH-stim test in some markets. Tier 2 for recreational GH release. Slightly more cortisol/prolactin elevation than ipamorelin.
Older GHRP with notable hunger-stimulation as a side effect (some users want this, most don't). Tier 3 for body-composition use; superseded by ipamorelin in most community protocols.
Most potent of the older GHRPs but also the most cortisol/prolactin elevation. Rarely the right first choice; community use is niche. Tier 3.
Downstream of the GH axis. Community use targets the same anabolic/recovery effects but skips the GH-pulse step. WADA-banned. Tier 3 outside formal endocrine indications.
Sleep
Peptides used to deepen overnight recovery. GH-axis peptides dosed at bedtime amplify the natural GH pulse, which several users report as deeper sleep. Direct sleep evidence is thin across the class — community reporting is consistent enough to mention but not strong enough to claim as proven.
Curated stack
- DSIPDelta Sleep Inducing Peptide acutely improves slow-wave (deep) sleep in the small studies that exist. Methodology is dated; community use is consistent enough to surface as part of the sleep core.
- CJC-1295 / IpamorelinBedtime GHRH + GHRP pairing aligns the injected GH pulse with the natural slow-wave-sleep GH window, deepening sleep secondarily. The dominant community sleep stack.
- SermorelinSingle-peptide GHRH alternative to CJC/Ipa for users who prefer a cleaner side-effect profile. Same protocol shape — bedtime, fasted.
- EpithalonPineal-acting tetrapeptide. Annual 20-day cycles claimed to restore age-related decline in endogenous melatonin secretion at the source, rather than substituting for it (as exogenous melatonin does).
- SelankAnxiolytic without sedation — useful when anxiety is driving sleep-onset problems rather than sleep architecture itself. Doesn't impair slow-wave or REM in the way benzodiazepines can.
The sleep stack pairs an acute slow-wave-promoting peptide (DSIP) with a bedtime GH-secretagogue pulse that lines up with the natural overnight GH window. Epitalon adds a longer-arc circadian/pineal layer; Selank handles the anxiety-driven onset problems that GH-axis peptides don't address. Direct human evidence is sparse across the class; the rationale is mechanistic with consistent community reporting.
More peptides in this goal
Bedtime ipamorelin (often paired with CJC-1295) is the dominant community sleep stack. Mechanistic basis: amplified overnight GH pulse, which some studies link to slow-wave sleep. Tier 3.
Same protocol shape as ipamorelin — bedtime, fasted. The two are typically co-administered. Tier 3.
The blend itself. Bedtime, fasted, paired with DSIP in many sleep protocols.
Similar mechanism to ipamorelin/CJC — boosts the natural overnight GH pulse. Older but well-characterized; some users prefer it for the cleaner side-effect profile. Tier 3 for sleep specifically.
Oral, taken at bedtime by many users specifically for the sleep-deepening effect. Real downside: sustained GH/IGF-1 elevation also brings water retention and sometimes morning grogginess. Tier 3.
Delta Sleep Inducing Peptide — discovered in the 1970s, hypothesized to promote slow-wave sleep. Human studies are small, old, and inconsistent. Community use is consistent enough to surface; the evidence base is thin. Tier 3.
Anxiolytic peptide; some users report better sleep onset rather than depth. Mechanism is anxiety-mediated, not GH-mediated. Tier 3 for sleep specifically.
Pineal-acting tetrapeptide. Annual cycles claimed to restore age-related melatonin decline; methodology of the underlying Russian work is contested. Tier 3.
Skin & hair
Topical applications dominate the evidence base here. Injectable / systemic claims for the same compounds are a separate evidence question and usually weaker.
Curated stack
- GHK-CuThe strongest-evidenced peptide for skin — multiple human topical RCTs showing measurable improvements in elasticity, thickness, fine lines, and photoaging markers over 8–12 weeks. Continuous SQ or topical.
- EpithalonAdds a telomerase-activation and skin-elasticity layer on top of the GHK-Cu base. Twice-yearly 20-day cycles per the Khavinson protocols.
- GlowGHK-Cu + BPC-157 + TB-500 blend marketed for skin and connective-tissue support. Convenience packaging of the topical/SQ peptides most associated with skin outcomes.
- BPC-157Subcutaneous repair adjunct for users with active skin wounds, scarring, or post-procedure recovery. Skin-specific human evidence is thin; the rationale draws on the broader soft-tissue repair animal data.
GHK-Cu carries the only Tier 2 human-RCT evidence for skin in this library; everything else is supportive layering. Topical and SQ routes are not interchangeable — the topical evidence does not directly transfer to injectable systemic claims. The hair-and-nail benefits commonly attributed to GH-axis peptides ride on IGF-1-driven fibroblast activity rather than peptide-specific skin trials.
More peptides in this goal
Tier 2 for topical skin and wound applications — multiple human studies on collagen synthesis, wound healing, and cosmetic outcomes. Tier 3 for injectable systemic use; the topical evidence does not transfer.
IV / oral glutathione is widely marketed for skin lightening, particularly in Asian cosmetic markets. Tier 3 for the cosmetic claim — small RCTs (Sonthalia 2018 review) report modest skin-tone changes; effect size is small.
Anti-aging skin claims circulate in compounding-clinic marketing. The underlying immunomodulation evidence is real (Tier 1 for chronic hep B/C); the leap to skin/hair outcomes is mechanism-as-evidence. Tier 4 for this specific use.
Russian-developed tetrapeptide with claimed skin-elasticity effects via telomerase activation. Western replication limited. Tier 3 for skin-specific claims.
Skin-focused blend (GHK-Cu + BPC-157 + TB-500). Convenience packaging; the component-level evidence drives the tier.
Subcutaneous repair adjunct. Animal soft-tissue evidence; skin-specific human data essentially absent. Tier 3.
Cognitive & nootropic
Peptides used to support cognitive function, mood, anxiety, and neuroprotection. Russian clinical practice contributes a meaningful share of the human data here; Western RCTs are scarcer. Two preclinical-only entries (Dihexa, P21) are surfaced honestly with that framing — community marketing routinely overstates them.
Nootropic + neurorestorative stack · 3 phases · guided multi-peptide program with decision criteria
Anxiolytic + neurotrophic peptide stack · 2 phases · guided multi-peptide program with decision criteria
Curated stack
- SemaxThe most direct nootropic on this list. ACTH(4-10)-derived peptide; works via BDNF and NGF upregulation. Intranasal, morning dosing. Tier 2 in Russian stroke and cognitive-decline indications; Tier 3 for healthy-adult nootropic use.
- SelankAnxiolytic heptapeptide. Russian RCT data showed comparable anxiolysis to benzodiazepines without sedation or dependence, plus mild cognitive enhancement. Stabilizes the stress response that often coexists with focus problems and pairs well with Semax through different receptor systems.
- NAD+Cellular-energy substrate. Layered in when cognitive symptoms have a fatigue or mitochondrial component.
- SS-31 (Elamipretide)Mitochondrial protection. Relevant specifically when fatigue and cognitive complaints co-occur; not a primary nootropic itself.
- Pinealon3-week neuroprotective cycle; pairs with Semax/Selank for longer-arc cognitive support beyond acute nootropic effect.
Semax and Selank are the workhorses — they target focus and stress-response on different receptor systems and stack well morning-dosed. The mitochondrial and NAD adjuncts are reserved for cognitive presentations that overlap with fatigue or post-illness energy decline, not as general nootropics. Russian clinical literature carries this stack; Western replication is limited, so tier conservatively.
More peptides in this goal
Russian-developed anxiolytic heptapeptide. Russian clinical studies report anxiolytic and cognitive-enhancement effects without sedation. Western trial data is limited. Tier 2 for anxiety in the Russian literature; Tier 3 for nootropic use elsewhere.
ACTH(4-10)-derived peptide. Russian clinical use in stroke, cognitive decline, and ADHD (intranasal). Tier 2 in those Russian indications; Tier 3 for healthy-adult nootropic use.
Porcine-brain-derived peptide mixture. Tier 2 for stroke recovery and vascular dementia in multiple meta-analyses. Western adoption is limited; community use as a high-end nootropic is supported by the disease-population evidence but is extrapolation in healthy adults.
Animal-only synaptogenic peptide. Foundational Wright/Harding-lab work has documented integrity issues (Athira / Kawas DOJ settlement, one paper retracted). One independent rodent replication (Sun 2021). Zero human trials. Tier 4 for human use — handle community claims accordingly.
Animal-only CNTF mimetic. Strong rodent data on hippocampal neurogenesis; zero human trials. Community marketing far exceeds what the evidence supports. Tier 4 for human use.
Cellular energy substrate. Layered into cognitive stacks when fatigue or post-illness energy decline accompanies the cognitive complaint. Tier 3 for this use.
Elamipretide. Mitochondrial protection. Tier 1 for Barth syndrome (FDA accelerated approval); Tier 4 for healthy-adult nootropic claims — not what the trials studied.
Khavinson tripeptide; 3-week neuroprotective cycles.
Sexual health & libido
Peptides used for libido, arousal, and intimacy. The strongest-evidence entry (PT-141 / bremelanotide) is FDA-approved for hypoactive sexual desire disorder; the community use for general libido enhancement is less well-supported.
Curated stack
- PT-141 (Bremelanotide)On-demand, 45–90 minutes pre-activity. FDA-approved as Vyleesi for premenopausal HSDD; the broader libido use draws on the same melanocortin mechanism. Best reserved for on-demand use due to the maximum 8-doses-per-month limit.
- KisspeptinSustained protocol targeting the GnRH/reproductive axis. Imperial College trials in HSDD show LH/FSH/testosterone elevation without desensitization in short-term use, suitable for ongoing dosing. Pairs with PT-141 because the two act on different brain pathways.
PT-141 (melanocortin) and kisspeptin (GnRH axis) hit different brain systems and can be combined — on-demand arousal layered on sustained HPG-axis support. The Tier 1 PT-141 evidence is for premenopausal HSDD specifically; broader libido claims are extrapolation. Kisspeptin's evidence base is for hypothalamic-amenorrhea and HSDD trials, not general libido enhancement in healthy users.
More peptides in this goal
Bremelanotide. FDA-approved as Vyleesi for premenopausal hypoactive sexual desire disorder. Tier 1 in that indication. Community use for general libido enhancement (any sex / situation) is Tier 3 — broader than the trials studied.
Tier 1 for childbirth and lactation. Tier 3 for the social/relational/sexual claims (intranasal oxytocin) — many small RCTs but heterogeneous outcomes and replication issues.
Tier 2 for hypothalamic amenorrhea / fertility induction (UK Imperial group). Some studies measure sexual response markers; the claim is more 'restores HPG-axis signaling' than 'enhances libido in the typical user'.
Melanocortin agonist. Community use for libido / spontaneous arousal effects. Same mechanism family as PT-141 but less selective and more side effects (nausea, pigmentation changes, atypical mole concerns). Tier 3 for libido use.
Skin pigmentation & tanning
Melanocortin-pathway peptides that drive melanogenesis. One has a real medical approval (Melanotan-1 / afamelanotide); the other is community-only. Surface mole monitoring becomes especially important on these — the same mechanism that darkens existing pigment can change atypical lesions.
Afamelanotide. FDA-approved as Scenesse for erythropoietic protoporphyria (EPP). Tier 1 in that indication. Off-label use for cosmetic tanning is Tier 3 and operates outside the safety surveillance the EPP indication has.
Synthetic α-MSH analog used by community for tanning + libido effects. Side-effect profile is real (nausea, blood-pressure changes, accelerated mole darkening). Multiple case reports of melanoma diagnoses associated with users. Tier 3 with non-trivial safety concerns.
Cellular longevity & mitochondrial
Compounds aimed at the cellular machinery of aging — NAD+ pathways, mitochondrial function, mTOR, senolytics. Most are not peptides (they are coenzymes or small molecules) but are surfaced here because the community routinely stacks them with peptide regimens. The evidence base ranges from one Phase 2 RCT in healthy adults (rapamycin / PEARL) to single mouse papers (FOXO4-DRI). Read each entry honestly.
Curated stack
- EpithalonTwice-yearly 20-day cycles per the Khavinson protocols. Targets the telomere-attrition hallmark of aging via claimed telomerase activation; methodology of the original Russian cohort studies is contested.
- GHK-CuContinuous SQ or topical. Targets epigenetic dysregulation and ECM degradation — the strongest skin-quality evidence in the library, with broader anti-aging extrapolation.
- NAD+Cycled. Restores the cofactor required for sirtuins, PARPs, and oxidative phosphorylation. IV/SubQ delivery is community-driven; oral precursors (NMN, NR) are better-studied.
- CJC-1295 / IpamorelinGH/IGF-1-axis restoration adjunct, addressing the GH decline hallmark of aging.
- SermorelinSingle-peptide GHRH alternative to CJC/Ipa for GH-axis restoration.
- MOTS-cMetabolic and exercise mimetic. Twice-yearly cycle pattern addresses mitochondrial-dysfunction hallmark of aging.
- SS-31 (Elamipretide)Mitochondrial cardiolipin stabilization. Twice-yearly 21-day cycle, offset from MOTS-c in the standard schedule.
- PinealonKhavinson tripeptide; longevity-context cellular-aging support, 21-day cycles twice yearly.
No single peptide addresses all the hallmarks of aging — the stack is the strategy. Epitalon (telomere attrition), GHK-Cu (epigenetic and ECM), NAD+ (cofactor decline), GH-axis (somatopause), MOTS-c/SS-31 (mitochondrial) — each component targets a separate axis. Cycle scheduling matters more than dose here: continuous GHK-Cu, periodic Epitalon and MOTS-c/SS-31, daily-five-on-two-off GH-axis dosing.
More peptides in this goal
Coenzyme — NOT a peptide. IV / SubQ NAD+ is heavily marketed by clinics; oral precursors (NMN, NR) are better-studied. Bioavailability and clinical-outcome questions remain genuinely contested. Tier 3 for most claims; Tier 4 for the clinic 'energy boost' framing.
Oral NAD+ precursor. Tier 2 for raising blood NAD+ (multiple human RCTs). Tier 3 for clinical outcomes — most healthy-adult endpoints have read out null or modest.
Oral NAD+ precursor, similar story to NR. Tier 2 for raising blood NAD+. Tier 3 for outcome claims. Regulatory status as a supplement was challenged by FDA in 2022.
Mitochondrial-derived peptide encoded by mtDNA. Animal data on insulin sensitivity, exercise capacity, and mitochondrial function. No completed human RCTs. Tier 3.
Elamipretide. Tier 1 for Barth syndrome (FDA accelerated approval 2024). Tier 2 for primary mitochondrial myopathy (mixed Phase 3). Tier 4 for general 'mitochondrial rejuvenation' marketing in healthy adults — that wasn't what the trials studied.
Russian-developed tetrapeptide. Khavinson group claims telomerase activation and lifespan effects. Western replication is limited; methodology questions on the original cohort studies are real. Tier 3 / Tier 4 depending on the indication.
Continuous SQ or topical. Anchors the ECM/skin axis of the broader longevity stack; topical evidence is Tier 2, injectable systemic is Tier 3.
GH-axis restoration adjunct. Tier 3 for longevity-framed use; mechanism is clean but outcome data is extrapolation.
Older GHRH analog. Tier 2 in approved indications, Tier 3 for adult longevity use.
mTOR inhibitor — NOT a peptide. Tier 1 for transplant rejection prophylaxis. Tier 3 for healthy-adult longevity use; the PEARL Phase 2 trial (2024-2025 readouts) is the largest data point and gave equivocal results.
Senolytic peptide. Single landmark mouse study (Baar 2017, Cell). Zero human trials. Vendor / longevity-clinic marketing runs orders of magnitude ahead of the science. Tier 4.
Khavinson tripeptide; longevity-context cellular-aging support.
Daily companion supplements
Vitamins and B-complex preparations frequently stacked with peptide regimens — especially relevant for users on metabolic peptides (GLP-1 / GIP class) where appetite suppression can produce real B-vitamin and D3 deficits. Tier 1 for actual deficiency states; the IV-clinic 'energy boost' framing in replete adults is Tier 4.
Methylated B12. Tier 1 for B12 deficiency. The community-preferred form for self-injection; the form-vs-cyanocobalamin debate is mostly theoretical for routine deficiency replacement.
Standard injectable B12 used in primary care. Tier 1 for B12 deficiency. Cheaper and more shelf-stable than methylcobalamin. Note: contraindicated in Leber's hereditary optic neuropathy — the one form-specific clinical concern.
Compounded injectable B-complex (B1+B2+B3+B5+B6+B12, sometimes B7/B9). Tier 1 for any actual B-vitamin deficiency, Wernicke's encephalopathy, post-bariatric maintenance. Tier 4 for the IV-clinic 'energy boost' marketing in replete adults.
Cholecalciferol. Tier 1 for vitamin D deficiency. Oral D3 is the right answer for the vast majority of users; injectable IM D3 is mostly for malabsorption / post-bariatric / compliance-failure populations. VITAL trial (Manson 2019) was largely null for prevention in unselected adults.
Post-surgical recovery
Tissue repair, infection-risk reduction, and immune support in the post-operative window.
Curated stack
- KlowBPC-157 + GHK-Cu + TB-500 + KPV blend, daily for 4–8 weeks depending on surgical severity. Covers the four major axes of post-surgical healing simultaneously: angiogenesis (BPC-157), gene-expression-level tissue regeneration (GHK-Cu), cell migration and anti-inflammation (TB-500), and intracellular NF-κB inhibition (KPV).
- BPC-157Standalone BPC-157 for severe localized trauma or when the patient cannot tolerate the full Klow blend. Same angiogenic mechanism as the BPC-157 component of Klow.
- Thymosin Alpha-1Immune support for major surgery or immunocompromised states. Supports T-cell function during the catabolic post-op phase; Tier 1–2 evidence base in approved indications.
- CJC-1295 / IpamorelinGH/IGF-1-mediated tissue repair in cases of severe tissue trauma. Bedtime dosing aligns the GH pulse with the natural overnight repair window.
- LL-37Broad-spectrum antimicrobial cathelicidin; post-surgical infection-risk reduction layered on top of the Klow tissue-repair core.
Klow provides simultaneous coverage of the major axes of post-surgical healing — angiogenesis, tissue regeneration, cell migration with anti-inflammation, and intracellular NF-κB inhibition. Begin within the first 1–2 weeks post-op once acute bleeding risk has cleared. Adjuncts layer in based on severity and infection risk: TA-1 for immunocompromise or major procedures, CJC/Ipa for tissue-heavy trauma, LL-37 for early antimicrobial coverage.
More peptides in this goal
BPC-157 + GHK-Cu + TB-500 + KPV blend. Convenience packaging of the post-surgical recovery core; tier follows the components — primarily Tier 3.
Standalone for severe trauma or near-site injection. Tier 3.
Immunomodulator. Tier 1–2 for chronic hepatitis B/C; post-surgical use draws on the immune-restorative framing during the catabolic post-op phase.
GH-axis tissue-repair adjunct for severe trauma. Tier 3 in this off-label context.
Antimicrobial cathelicidin used post-surgically for infection-risk reduction.
Tendon, ligament & soft-tissue injury
Athletic injuries, chronic tendinopathy, post-injury recovery, and connective-tissue repair.
Curated stack
- WolverineBPC-157 + TB-500 blend — the most evidence-supported soft-tissue combination in the preclinical literature. Sikiric's rat models show accelerated Achilles tendon and medial collateral ligament repair without scar tissue formation.
- GHK-CuStrengthens the collagen and elastin synthesis component of the repair process. Layered onto Wolverine when connective-tissue density is the limiting factor.
- CJC-1295 / IpamorelinGH/IGF-1 elevation independently drives connective-tissue repair and is a known driver of training-induced tissue adaptation. Pre-bed dosing aligns with the natural overnight repair window.
- BPC-157Standalone BPC-157 for localized injection near the injury site when anatomically feasible — concentrates the angiogenic effect at the lesion rather than relying on systemic distribution.
BPC-157 + TB-500 (the Wolverine blend) is the most evidence-supported soft-tissue combination in the preclinical literature, with consistent rat data on tendon and ligament repair. GHK-Cu strengthens the collagen-synthesis arm, and a GH secretagogue adds IGF-1-driven adaptation. WADA-banned components — this stack applies only in non-competition contexts.
More peptides in this goal
BPC-157 + TB-500 blend. Convenience packaging of the soft-tissue repair core; tier follows the components — Tier 3 across both.
Standalone for local injection near the injury site. Tier 3.
Collagen and elastin synthesis support. Topical Tier 2 in dermal applications; soft-tissue extrapolation is Tier 3.
GH/IGF-1 axis adjunct for connective-tissue repair. Tier 3 in this off-label context.
Perimenopause support
Hormonal volatility (mood swings, sleep disruption, brain fog, anxiety) before periods fully stop. Not a substitute for HRT where indicated.
Curated stack
- DSIPSleep-disruption is often the first peri symptom. DSIP acutely restores slow-wave sleep; pairs with a bedtime GH secretagogue for compounded overnight recovery.
- SelankAnxiolytic without sedation or dependence — particularly useful for the volatile mood pattern of peri. Doesn't impair sleep architecture the way benzodiazepines can.
- CJC-1295 / IpamorelinOvernight GH pulse preserves lean mass as metabolism slows and supports sleep architecture and recovery.
- SemaxCognitive overlap — brain fog and concentration complaints are common in peri. Morning intranasal dosing.
- BPC-157GI overlay — bloating, IBS-like symptoms, and gut sensitivity often emerge or worsen in this window. Pairs with KPV for the inflammation arm.
- KPVAnti-inflammatory adjunct for the GI overlay common in peri — bloating, food sensitivity, IBS-like patterns.
- GHK-CuEarly skin changes (loss of elasticity, drier texture) start in peri before becoming pronounced postmenopause. Continuous SQ or topical.
- TesamorelinOptional substitute for CJC/Ipa when visceral fat is the dominant body-composition complaint.
- PinealonKhavinson tripeptide; 21-day cognitive-protective cycle for the brain-fog component of peri.
Perimenopausal symptoms are driven more by hormonal volatility than absolute deficiency, so the stack emphasizes nervous-system stabilization (Selank), sleep architecture (DSIP, GH secretagogue), and supporting the axes that are starting to decline (GH/IGF-1, gut barrier, skin collagen). Symptoms can be cyclical with the irregular cycles, so PRN flexibility is valuable. Not a substitute for HRT where indicated.
More peptides in this goal
Slow-wave sleep restoration for the sleep-disruption that often leads the peri picture. Tier 3.
Anxiolytic for the volatile mood pattern of peri. Tier 2 in Russian GAD literature; Tier 3 for peri-specific use.
Overnight GH pulse — lean-mass preservation and sleep architecture support. Tier 3 in this off-label context.
Cognitive/brain-fog adjunct. Tier 2 in Russian cognitive indications; Tier 3 for peri-specific use.
GI overlay for peri-onset bloating and gut sensitivity. Tier 3.
Anti-inflammatory adjunct for the GI overlay. Tier 3.
Early skin-change support. Topical Tier 2 evidence; SQ extrapolation Tier 3.
Visceral-fat substitute for CJC/Ipa when body-composition complaints dominate. Tier 1 for HIV lipodystrophy; Tier 2 off-label for non-HIV visceral fat.
Khavinson tripeptide; cognitive support for peri brain fog.
Postmenopause support
Sustained low estrogen and downstream changes (bone, skin, libido, mitochondrial function). Not a substitute for HRT where indicated.
Curated stack
- GHK-CuContinuous SQ or topical. The most evidence-supported peptide for skin elasticity and density — postmenopausal skin and hair changes become more pronounced and respond to sustained dosing.
- EpithalonAnnual 20-day cycle for cellular aging and skin-elasticity layering. Targets the telomere-attrition arm of the postmenopausal aging picture.
- TesamorelinFDA-approved specifically for visceral fat reduction (in HIV lipodystrophy context). Visceral-fat accumulation is a defining postmenopausal body-composition change; the strongest evidence base of any GHRH analog.
- MOTS-cMitochondrial decline is part of the postmenopausal energy picture. Twice-yearly cycle alongside SS-31 and NAD+ for the cellular-energy arm.
- SS-31 (Elamipretide)Cardiolipin stabilization at the inner mitochondrial membrane. Twice-yearly 21-day cycle, offset from MOTS-c.
- NAD+Cycled. Restores the cofactor required for sirtuins, PARPs, and oxidative phosphorylation — the same metabolic axis that declines postmenopause.
- PT-141 (Bremelanotide)On-demand for sustained low libido and sexual function — operates on the melanocortin pathway, complementing rather than replacing HRT.
- KisspeptinSustained protocol per the Imperial College HSDD trials in pre- and postmenopausal women. Pairs with PT-141 because the two act on different brain pathways.
- CJC-1295 / IpamorelinBone density and lean-mass support via the GH/IGF-1 axis, which indirectly supports bone formation.
Postmenopausal physiology is shaped by sustained low estrogen and its downstream effects on bone, skin, sleep architecture, libido, mitochondrial function, and cardiovascular risk. The stack emphasizes restoration of declining systems (GH/IGF-1, NAD+, mitochondrial function) and addressing symptoms that don't fully respond to HRT alone (libido via central pathways, skin via GHK-Cu, mitochondrial decline). A menopause-trained clinician should be involved — peptides complement rather than replace appropriate HRT.
More peptides in this goal
Continuous skin/hair support. Topical Tier 2; SQ extrapolation Tier 3.
Annual 20-day cycle for cellular aging and skin elasticity. Tier 3.
Visceral fat reduction. Tier 1 in HIV lipodystrophy; Tier 2 off-label.
Mitochondrial-decline adjunct. Tier 3.
Mitochondrial cardiolipin stabilization. Tier 1 for Barth syndrome; Tier 4 for general 'rejuvenation' framing in healthy adults.
Cycled cellular-energy adjunct. Tier 3.
On-demand libido support. Tier 1 for premenopausal HSDD; Tier 3 for broader libido in postmenopausal women.
Sustained HPG-axis support. Tier 2 for HSDD trials.
Bone-density and lean-mass support via GH/IGF-1. Tier 3 in this off-label context.
Mitochondrial repair & low energy
Chronic fatigue, cellular energy decline, brain fog, post-viral fatigue, and the energy decline of normal aging.
Curated stack
- SS-31 (Elamipretide)Stabilizes cardiolipin and the electron transport chain at the inner mitochondrial membrane. Tier 1 for Barth syndrome; mitochondrial-repair framing in healthy adults is mechanistic.
- MOTS-cMitochondrial-derived peptide. Acts as an exercise mimetic via AMPK and improves insulin sensitivity. Twice-yearly cycle alongside SS-31.
- NAD+Restores the cofactor required for sirtuins, PARPs, and oxidative phosphorylation. Cycled 6-on / 1-off in the standard schedule.
- GlutathioneReduces the oxidative damage that limits mitochondrial function. Useful when oxidative stress markers or chronic illness presentation suggest a redox imbalance.
- SelankCognitive-fatigue overlap. Stabilizes the stress response that often coexists with energy complaints.
- SemaxCognitive-fatigue overlap. Direct nootropic via BDNF/NGF — useful when brain fog is the leading symptom of the energy picture.
The mitochondrial stack targets multiple convergent drivers of cellular energy decline simultaneously. SS-31 stabilizes the electron-transport-chain membrane; MOTS-c improves insulin sensitivity and acts as an exercise mimetic; NAD+ restores the depleted cofactor pool. Glutathione layers redox protection on top. The two anxiolytic/cognitive adjuncts (Selank, Semax) address the cognitive-fatigue overlap that frequently accompanies a primary mitochondrial picture.
More peptides in this goal
Elamipretide. Tier 1 for Barth syndrome; mitochondrial-rejuvenation framing in healthy adults is Tier 4.
Mitochondrial-derived peptide. Tier 3 — no completed human RCTs.
IV/SubQ NAD+ cofactor restoration. Tier 3.
Oxidative-stress reduction adjunct. Tier 3 for the chronic-fatigue framing.
Cognitive-fatigue overlap. Tier 2 in Russian anxiety literature; Tier 3 for this use.
Cognitive-fatigue overlap. Tier 2 in Russian cognitive indications; Tier 3 for general nootropic use.
Gut health, IBD & intestinal barrier
Gastrointestinal repair, intestinal-permeability ('leaky gut') support, and inflammatory bowel contexts.
Curated stack
- BPC-157Originally isolated from gastric juice; remains the best-evidenced peptide for GI mucosal repair. Promotes angiogenesis and maintains barrier integrity in rodent models of colitis and ulceration.
- KPVInhibits NF-κB nuclear translocation in intestinal epithelium via the PepT1 transporter — which is upregulated specifically in inflamed gut, giving KPV selectivity for diseased tissue.
- LarazotideTight-junction integrity. Targets the zonulin pathway in celiac and 'leaky gut' contexts where barrier permeability is the leading mechanism.
- GHK-CuGI epithelial repair layering. Adds the ECM/regeneration arm that BPC-157 and KPV don't directly cover.
- Thymosin Alpha-1Immune modulation for chronic GI inflammation and autoimmune GI disease (Crohn's, UC). The Tier 1–2 immunomodulation evidence base translates to the immune-dysregulation arm of IBD.
BPC-157 and KPV act on complementary axes — tissue repair plus inflammation control — and KPV's PepT1 selectivity for inflamed gut means the anti-inflammatory effect concentrates where it's needed. Larazotide adds tight-junction integrity for barrier-led presentations; TA-1 handles the immune-dysregulation arm of chronic IBD. No published human RCTs for BPC-157 or KPV in IBD specifically; the rationale is mechanistic with consistent rodent colitis data.
More peptides in this goal
GI mucosal repair. Strong rodent colitis data; one small uncontrolled human case series. Tier 3.
NF-κB inhibition in inflamed gut epithelium via PepT1 selectivity. Tier 3.
Tight-junction modulator. Phase 3 trials in celiac disease (read out 2021); not FDA-approved as of publication. Tier 2 for celiac, Tier 3 for broader 'leaky gut' framing.
GI epithelial repair extrapolation from dermal evidence. Tier 3 in this use.
Immune modulation for autoimmune GI disease. Tier 1–2 base; IBD-specific extrapolation Tier 3.
Athletic performance & recovery
Training adaptation, recovery, and connective-tissue resilience in athletic populations.
Curated stack
- CJC-1295 / IpamorelinPulsatile GH elevation for recovery between hard sessions. CJC no-DAC is preferred over with-DAC for athletic use because the short half-life pulse mimics physiologic GH release patterns rather than sustained elevation.
- WolverineBPC-157 + TB-500 blend. The soft-tissue repair foundation — accelerated tendon and ligament repair in preclinical models.
- MOTS-cExercise mimetic via AMPK. Twice-yearly cycle for mitochondrial efficiency and endurance bioenergetics.
- IGF-1 LR3Direct IGF-1 administration — skips the GH-pulse step. Monitoring-intensive (insulin sensitivity, glycemic response). WADA-banned.
- GHK-CuConnective-tissue support during high-volume training phases. Layers onto Wolverine when collagen synthesis is the rate-limiting factor.
Soft-tissue repair plus pulsatile GH elevation for recovery, plus mitochondrial support for endurance and bioenergetics. CJC no-DAC is the athletic choice over with-DAC because the short half-life mimics physiologic GH release more closely than sustained elevation. WADA caveat: BPC-157, TB-500, and any GH secretagogue are banned for competitive athletes — this stack applies only in non-competition contexts.
More peptides in this goal
Athletic GH-pulse pairing. WADA-banned. Tier 3 in this off-label use.
BPC-157 + TB-500 blend. WADA-banned. Tier 3 across the soft-tissue claims.
Exercise-mimetic adjunct. Tier 3.
Direct IGF-1. WADA-banned. Tier 3 outside formal endocrine indications.
Connective-tissue support. Topical Tier 2; SQ/athletic extrapolation Tier 3.
Immune support
Chronic illness recovery, antimicrobial coverage, and immune modulation.
Curated stack
- Thymosin Alpha-1The best-evidenced immune modulator in this library, with decades of pharmaceutical use as Zadaxin across 35+ countries. Modulates rather than simply stimulates — drives T-cell maturation, reduces immune-exhaustion markers (PD-1, TIM-3), with efficacy data in viral hepatitis and immune-reconstitution contexts.
- LL-37Direct antimicrobial activity; pairs with TA-1 for immune-modulation + antimicrobial coverage in chronic infection or immune-suppressed states.
Thymosin alpha-1 is the foundation — Tier 1 evidence base in approved markets for chronic viral hepatitis and as an immune adjuvant. The standard adjunct layering (LL-37 for direct antimicrobial coverage, BPC-157 for gut-barrier immune-homeostasis support, Selank for the stress-immune axis, Glutathione for chronic-illness oxidative stress) extends the stack.
More peptides in this goal
Immune modulator. Tier 1–2 across approved chronic viral hepatitis and adjunctive cancer immunotherapy contexts.
Direct antimicrobial; pairs with TA-1 for immune coverage.
Anxiety, stress & mood
Anxiolysis without sedation and stabilization of mood/affect.
Curated stack
- SelankThe most direct anxiolytic in this stack. Russian RCT data showed comparable anxiolysis to benzodiazepines (medazepam) without sedation or dependence, plus mild cognitive enhancement absent from the benzodiazepine arm. Morning dosing, 21-day cycles.
- SemaxCognitive co-load support. ACTH(4-10)-derived peptide upregulates BDNF and NGF; addresses the focus and mental-clarity friction that often coexists with anxiety. Morning intranasal dosing.
- DSIPSleep-disruption overlap. Delta Sleep Inducing Peptide restores slow-wave sleep when stress and anxiety are fragmenting sleep architecture.
Anxiety and stress combine nervous-system instability with disrupted sleep. The stack stabilizes both — Selank handles the acute anxiolytic load via different receptor systems than benzodiazepines (no sedation or dependence in Russian RCT data), Semax addresses the cognitive friction that often coexists with anxiety, and DSIP restores slow-wave sleep when stress is disrupting sleep architecture.
More peptides in this goal
Russian-developed anxiolytic heptapeptide. Zozulya et al. (2008) RCT compared Selank to medazepam in 30 GAD patients, showing comparable anxiolysis without sedation or dependence, plus mild cognitive enhancement. Approved in Russia for GAD since 2009. Tier 2 in Russian literature; Tier 3 for use outside approved indications.
ACTH(4-10)-derived peptide. Russian clinical use in stroke, cognitive decline, and ADHD (intranasal). Tier 2 in those Russian indications; Tier 3 for healthy-adult nootropic use or as anxiety adjunct.
Delta Sleep Inducing Peptide — discovered in the 1970s, hypothesized to promote slow-wave sleep. Human studies are small, old, and inconsistent. Community use is consistent enough to surface; the evidence base is thin. Tier 3 for sleep-disruption-related anxiety.
Or build a stack in one shot
Pick the goals that matter to you and we’ll pre-fill a stack with sensible doses, frequencies, and vial sizes. Adjust anything inline. One submit and they’re all on your stack page.
Open the stack builder